Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.3
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
9 Months Ended
Sep. 30, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended September 30, 

Nine-Month Periods Ended September 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza®

$

7,583

$

5,865

$

19,435

$

18,038

Accutane®

 

3,996

 

4,882

 

15,534

 

15,109

Amzeeq®

1,542

2,336

3,503

4,904

Zilxi®

558

681

1,200

1,567

Other / legacy

950

1,515

2,842

4,787

Total product revenues

$

14,629

$

15,279

$

42,514

$

44,405

Schedule of other revenue

    

Three-Month Periods Ended September 30,

    

Nine-Month Periods Ended September 30,

($in thousands)

2024

    

2023

2024

    

2023

Non-refundable upfront payment from Maruho

 

$

 

$

19,000

 

$

 

$

19,000

Royalties on sales of Rapifort® Wipes 2.5%

260

519

Total other revenue

$

$

19,260

$

$

19,519